Search This Blog

Wednesday, October 2, 2019

ArQule launches registrational study of miransertib in PS and PROS

ArQule (NASDAQ:ARQL) doses first patient in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS).
The study will enroll approx. 30-35 patients to evaluate the objective response to miransertib in patients with PS and PROS. Same number of patients will be enrolled in 2 other cohorts for patients under compassionate use or those ineligible to enter the registrational cohorts.
https://seekingalpha.com/news/3503283-arqule-launches-registrational-study-miransertib-ps-pros

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.